Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Executive Summary | 1 | 3 |
| 2 Table of Contents | 4 | 3 |
| 2.1 List of Tables | 6 | 1 |
| 2.2 List of Figures | 6 | 1 |
| 3 The Future of Contract Sales Organizations Introduction | 7 | 1 |
| 3.1 GBI Research Report Guidance | 7 | 1 |
| 4 The Future of Contract Sales Organizations Market Overview | 8 | 6 |
| 4.1 Introduction | 8 | 1 |
| 4.2 CSOs Major Services | 9 | 1 |
| 4.2.1 Contract Sales Representatives | 9 | 1 |
| 4.2.2 Sales Team Recruitment and Training | 9 | 1 |
| 4.2.3 Sales Data Analytics and Management | 10 | 1 |
| Shared Sales Teams &Telesales | 10 | 1 |
| 4.2.5 Medical Science Liaisons | 11 | 1 |
| Pharma Sales Model Traditional vs Evolving Model | 11 | 2 |
| 4.4 Key Takeaway | 13 | 1 |
| 5 The Future of Contract Sales Organizations Market Characterization | 14 | 13 |
| 5.1 Introduction | 14 | 1 |
| 5.1.1 Market Size | 14 | 1 |
| 5.1.2 Geographic Concentration | 15 | 1 |
| 5.2 Why CSOs? | 16 | 1 |
| 5.2.1 Reduce Costs | 16 | 1 |
| 5.2.2 Enable Strategic Flexibility with Sales Force | 17 | 1 |
| 5.2.3 Increase Speed-to-Market for Newly Launched Drugs | 18 | 1 |
| 5.2.4 Access to Expertise in New Markets/Product Category and Avoiding Upfront Investments | 19 | 1 |
| 5.2.5 Build Strategic Partnerships with Healthcare Authorities | 19 | 1 |
| 5.2.6 Removing Redundancies Focusing on Core Activities | 20 | 1 |
| 5.3 Factors Driving and Restraining the Contract Sales Outsourcing Market | 21 | 1 |
| 5.3.1 Drivers | 21 | 1 |
| 5.3.1.1 Erosion of Blockbuster Drugs | 21 | 1 |
| 5.3.1.2 Rising Cost and Difficulty in Selling Drugs Expensive Sales Representatives | 22 | 1 |
| 5.3.1.3 Changing Market Landscape Increased Use of Specialized Medicines | 22 | 1 |
| 5.3.1.4 Global Pharmaceutical Companies Lack of Local Knowledge in Emerging Markets | 23 | 1 |
| 5.3.1.5 Increasing Importance of Stronger Customer Relationship | 23 | 1 |
| 5.3.2 Barriers | 24 | 1 |
| 5.3.2.1 Price Competition Impact on Quality of Services | 24 | 1 |
| 5.3.2.2 Skills Shortage in Specialized Secondary Care | 24 | 1 |
| 5.3.2.3 Limitations in Outsourcing the Amount of Sales Force | 25 | 1 |
| 5.4 Key Takeaway | 26 | 1 |
| 6 The Future of Contract Sales Organizations Regulatory Landscape | 27 | 5 |
| 6.1 Prescription Drug Marketing Act (PDMA) | 27 | 1 |
| 6.2 Title 21 Code Of Federal Regulations, Part 11 (21 CFR Part 11) | 27 | 2 |
| 6.3 EFPIA (European Federation of Pharmaceutical Industries and Associations) Code on the Promotion of Prescription Only Medicines to, and Interactions with, Healthcare Professionals | 29 | 1 |
| 6.4 ABPI (Association of the British Pharmaceutical Industry) Code of Practice for the Pharmaceutical Industry | 29 | 1 |
| 6.5 PhRMA s (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals | 30 | 1 |
| 6.6 OIG (Office of Inspector General) Guidelines for Industry | 31 | 1 |
| 6.7 Key Takeaway | 31 | 1 |
| 7 The Future of Contract Sales Organizations Competitive Landscape | 32 | 20 |
| 7.1 Selecting a CSO | 32 | 1 |
| 7.1.1 Price | 32 | 1 |
| 7.1.2 Service Portfolio | 32 | 1 |
| 7.1.3 Experience | 33 | 1 |
| 7.1.4 Time Efficiency | 33 | 1 |
| 7.1.5 Resources | 33 | 1 |
| 7.1.6 Reputation | 33 | 1 |
| 7.2 Major Companies in the Contract Sales Outsourcing Market | 34 | 1 |
| 7.2.1 inVentiv Health (inVentiv Selling Solutions) | 34 | 1 |
| 7.2.1.1 Business Description | 34 | 1 |
| 7.2.1.2 Services Offered | 35 | 1 |
| 7.2.1.3 Major Deals | 35 | 2 |
| 7.2.2 Pharmexx | 37 | 1 |
| 7.2.2.1 Business Description | 37 | 1 |
| 7.2.2.2 Services Offered | 37 | 1 |
| 7.2.2.3 Major Deals | 38 | 1 |
| 7.2.3 OnCall LLC | 39 | 1 |
| 7.2.3.1 Business Description | 39 | 1 |
| Major Services | 39 | 1 |
| 7.2.3.3 Major Deals | 40 | 1 |
| 7.2.4 Publicis Selling Solutions | 41 | 1 |
| 7.2.4.1 Business Description | 41 | 1 |
| Major Services | 41 | 1 |
| 7.2.4.3 Major Deals | 42 | 1 |
| 7.2.5 Quintiles (Innovex) | 43 | 1 |
| 7.2.5.1 Business Description | 43 | 1 |
| 7.2.5.2 Services Offered | 43 | 1 |
| 7.2.5.3 Major Deals | 44 | 1 |
| 7.2.6 Professional Detailing Inc | 45 | 1 |
| 7.2.6.1 Business Description | 46 | 1 |
| 7.2.6.2 Services Offered | 46 | 1 |
| 7.2.6.3 Major Deals | 47 | 1 |
| 7.2.7 Ashfield In2Focus Ltd | 48 | 1 |
| Business Description | 48 | 1 |
| 7.2.7.2 Services Offered | 48 | 1 |
| 7.2.7.3 Major Deals | 49 | 1 |
| 7.2.8 Vanguard Pharma | 50 | 1 |
| 7.2.8.1 Business Description | 50 | 1 |
| 7.2.8.2 Services Offered | 50 | 1 |
| 7.2.8.3 Major Deals | 50 | 1 |
| 7.3 Key Takeaway | 51 | 1 |
| 8 The Future of Contract Sales Organizations Deals Analysis | 52 | 12 |
| 8.1 Service Contracts Landscape | 52 | 1 |
| 8.1.1 Contract Sales Deals by Client Type Equally Dominated by Small, Mid, Big and Specialty Pharma | 52 | 1 |
| 8.1.2 Contract Sales Deals by Service Area Recruitment and Training Services in Highest Demand as Value Added Services | 53 | 1 |
| 8.1.3 Contract Sales Deals by Geography the US and Europe Remain the Central Focus | 54 | 1 |
| 8.1.4 Major Contract Sales Deals | 54 | 1 |
| 8.1.4.1 Quintiles the UK based Biotechnology Company | 54 | 1 |
| 8.1.4.2 Quintiles (NovaQuest) Eli Lilly | 55 | 1 |
| 8.1.4.3 PDI Major Pharmaceutical Company | 55 | 1 |
| 8.1.4.4 Publicis Selling Solutions (TLC) Specialty Pharmaceutical Company | 55 | 1 |
| 8.1.4.5 Publicis Selling Solutions Specialty Pharmaceutical Company | 56 | 1 |
| 8.2 M&A Landscape | 57 | 1 |
| 8.2.1 Ashfield merges with In2focus | 57 | 1 |
| 8.2.2 THL (Thomas H. Lee) Partners acquires inVentiv Health | 57 | 1 |
| 8.2.3 Ashfield In2Focus acquires Universal and BEST (Business Edge Solutions and Training Limited) | 57 | 1 |
| 8.2.4 Publicis Groupe s acquisition of Pharmagistics | 58 | 1 |
| 8.2.5 inVentiv Health acquires ASERT (American Speakers Education Research Training) and DialogCoach | 59 | 1 |
| 8.2.6 Celesio AG acquired Alchemy Healthcare (Ireland) Limited and buys majority stake in Pharmexx GmbH | 60 | 1 |
| 8.2.7 Other Strategic Alliances among CSOs | 61 | 1 |
| 8.2.7.1 PDI partners with Physicians Interactive | 61 | 1 |
| 8.2.7.2 PDI partners with TMAC (The Medical Affairs Company) | 61 | 1 |
| 8.2.7.3 Quintiles (Innovex) partners with J. Knipper &Company | 62 | 1 |
| 8.3 Key Takeaway | 63 | 1 |
| 9 The Future of Contract Sales Organizations Future Opportunities and Challenges | 64 | 3 |
| Emerging Markets to Fuel the Future Growth | 64 | 1 |
| 9.2 Capabilities, And Not Only Price, Will Play a Key Role in CSO Selection | 65 | 1 |
| 9.3 Regulations in Emerging Markets will Determine the Growth of Future Contract Sales Market | 66 | 1 |
| 9.4 Key Takeaway | 66 | 1 |
| 10 The Future of Contract Sales Organizations Conclusion | 67 | 1 |
| 11 The Future of Contract Sales Organizations Appendix | 68 | 4 |
| 11.1 Market Definitions | 68 | 1 |
| 11.2 Abbreviations | 68 | 1 |
| 11.3 Research Methodology | 69 | 2 |
| 11.3.1 Coverage | 69 | 1 |
| 11.3.2 Secondary Research | 70 | 1 |
| 11.3.3 Primary Research | 70 | 1 |
| 11.3.4 Expert Panel Validation | 70 | 1 |
| 11.4 Contact Us | 71 | 1 |
| 11.5 Disclaimer | 71 | 1 |
| 11.6 Sources | 71 | 1 |